Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...
Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...
Biogen Inc., is a leading biotechnology company, announced the initiation of dosing in the global clinical study, TRANSCEND. The phase 3 study will evaluate the efficacy and safety of the ...
CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety ...
Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...
Clinical Trials Arena on MSN22d
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMRIn Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.
Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback